LicianPro

Theravance Biopharma, Inc. ·

TBPH 8-K 2026-09-23

Theravance Biopharma, Inc. (TBPH) 8-K dated 2026-09-23 — accession 0001104659-26-109979.

Theravance Biopharma, Inc. (TBPH) is a biotechnology company listed on NASDAQ.

Theravance Biopharma, Inc. filed a 8-K on 2026-09-23. Accession 0001104659-26-109979.

This 8-K covers: Material agreement (Item 1.01), Acquisition or disposition (Item 2.01), Listing notice (Item 3.01), Change to holders' rights (Item 3.03), Change in control (Item 5.01), Director/officer change (Item 5.02). SEC EDGAR holds the official filing and its exhibits.

Latest reported TBPH revenue for 2025-12-31 was $107.5M. Net income was $105.9M. Revenue was up 66.9% from 2024-12-31 to 2025-12-31. TBPH currently screens at market cap $861.5M.

Not investment advice. The TBPH SEC hub lists recent forms. The stock page is the research view.

Open on SEC EDGAR

These filings as JSON? API free 100/day

Lician Pro $19.99/mo or $149/yr